As more firms and investors look to SPACs as an IPO alternative, will this change the way biotech companies access public markets long-term? Our investment banking team goes inside the SPAC boom to explain what companies need to know before choosing their path to going public.

In this episode of Pathfinders, Brian Abrahams, Managing Director and Co-Head of Biotechnology Equity Research at RBC Capital Markets speaks with Andy Schwab, Co-Founder and Managing Partner at 5AM Ventures.

• Prescription Digital Therapeutics will be vital to future treatment
• Unlocking microbiome could lead to better disease management

Luca Issi, Senior Biotechnology Research Analyst at RBC Capital Markets, discusses the art of building biopharma breakthroughs with Arjun Goyal, Co-Founder and Managing Director of Vida Ventures.

• Maturation of the industry is increasing innovation and capital inflows
• Strong science, management and investors can keep the IPO window open

Even in a boom, many biotech executives may be unprepared for the risks involved in undertaking an IPO. Noël Brown and Tim Papp, Managing Directors focused on biotechnology in our Global Healthcare Investment Banking and Jason Levitz, Head of Healthcare Equity Capital Markets at RBC Capital Markets discuss the right steps to take, and the pitfalls to avoid, in today’s markets.

In our launch edition of Pathfinders, we look at the best practices to follow on the road to IPO and the new predictive factors for success in today’s buoyant biopharma markets.